Tolerogenic Interactions of 4-1BB
Tolerogenic Interactions of 4-1BB
批准号:
7771080
负责人:
Michael Croft
金额:
$23.61万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-02-10 至 2011-01-31
关键词:
AccountingAgeAnimalsAntigensAutoimmune DiseasesAutoimmune ProcessAutoimmunityBindingBiologyCancerousCell divisionCell surfaceCellsCessation of lifeCharacteristicsChronicDataDendritic CellsDevelopmentDiseaseFailureFamilyGalactose Binding LectinGalectin 3GenesGoalsGrantHematopoiesisImmuneImmune responseImmune systemImmunityInduction of ApoptosisInflammationKnowledgeLeadLigandsLigationMature T-LymphocyteMediatingMolecularMusNaturePhenotypeRegulationRegulatory T-LymphocyteReportingRoleSignal TransductionSurfaceSymptomsT cell responseT-LymphocyteTNF geneTestingTumor Necrosis Factor Receptorbasemembernovelpathogenpublic health relevancereceptorresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The failure of T cell tolerance can lead to spontaneous inflammation and at worst autoimmune disease. The control of T cell tolerance versus immunity in part relies on signals from co-stimulatory and co-inhibitory receptors that control various activities of T cells. 4-1BB (CD137, ILA, TNFRSF9), a member of the tumor-necrosis factor receptor (TNFR) super-family, was originally identified as an inducible co-stimulatory molecule on activated T cells. The ligand of 4-1BB (4-1BBL, TNFSF9), a member of the TNF super-family, expressed on activated APC binds to 4-1BB that is induced on T cells, generating positive signals inside T cells to help them function and to augment various aspects of immunity. In contrast we have found an inhibitory role for 4-1BB that does not rely on interaction with 4-1BBL. The absence of 4-1BB, in gene-deficient animals, leads to an enhanced rather than suppressed responsiveness of T cells to specific antigen, and 4-1BB-deficient mice spontaneously generate autoimmune-type phenotypes with chronic inflammation at the mucosal interfaces, a phenotype not seen in 4-1BBL-deficient mice. Our hypothesis is that 4-1BB binds with unidentified ligands that are constitutively expressed or induced early in an immune response to limit T cell reactivity and maintain tolerance, but by switching partners to 4-1BBL expressed later with inflammation, 4-1BB can then provide a positive stimulatory action. Our preliminary results have identified both galectin-3 and galectin-9, two reported suppressive molecules, as partners for 4- 1BB. The studies in this grant will investigate the interaction of galectins with 4-1BB and determine whether 4-1BB/galectin interactions account for 4-1BB negatively regulating T cell responsiveness. The identification and characterization of novel binding partners for 4-1BB will provide new understanding into 4-1BB biology as well as T cell tolerance and chronic inflammation.
PUBLIC HEALTH RELEVANCE: 4-1BB and its ligand(s) are expressed on the surface of many immune cells and are thought to regulate the ability to mount an immune response. 4-1BB provides essential signals to a T cell to allow it to continue dividing late in its response, and to suppress excessive death. However, 4-1BB interactions also act as a rate-limiting step to control initial T cell division and expansion. By understanding where and when 4-1BB and its ligand(s) are expressed, and the functional importance of these putative interactions, we will gain knowledge that might lead to ways to either enhance or suppress T cell responses, and so might be therapeutically relevant in a number of disease settings such as in limiting autoimmunity, or augmenting the ability to respond to cancerous cells or infectious pathogens.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.4049/jimmunol.1700575
发表时间:
2017-10-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Madireddi S, Eun SY, Mehta AK, Birta A, Zajonc DM, Niki T, Hirashima M, Podack ER, Schreiber TH, Croft M]
通讯作者:
Croft M
TWEAK and Skin Inflammation
-
批准号:10400699
-
项目类别:
-
资助金额:$39.2万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
-
批准号:10531229
-
项目类别:
-
资助金额:$51.26万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
Immune Regulation by Deubiquitination
-
批准号:9982199
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
-
批准号:10053328
-
项目类别:
-
资助金额:$52.31万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
TWEAK and Skin Inflammation
-
批准号:9910059
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
-
批准号:10310411
-
项目类别:
-
资助金额:$51.26万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
TWEAK and Skin Inflammation
-
批准号:10152528
-
项目类别:
-
资助金额:$38.41万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
Immune Regulation by Deubiquitination
-
批准号:9788250
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:9321444
-
项目类别:
-
资助金额:$33.47万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:10675443
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:10269804
-
项目类别:
-
资助金额:$37.53万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:10458735
-
项目类别:
-
资助金额:$33.27万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Novel PTPRD interaction Controlling T cell Responsiveness
-
批准号:9077779
-
项目类别:
-
资助金额:$26.55万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Structural Characterization of 4-1BB-Galectin-9 Complexes
-
批准号:8679808
-
项目类别:
-
资助金额:$8.85万
-
财政年份:2014
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:8577804
-
项目类别:
-
资助金额:$41.6万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:8661698
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Novel costimulatory pathways required for T cell regulation
-
批准号:8495230
-
项目类别:
-
资助金额:$43.81万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:9267076
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:9054041
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:8839196
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: